搜索临床试验以:白蛋白-紫杉醇、阿帕替尼、Camrelizumab
总计1328个结果
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.尚未招聘
-
Fujian Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.; SunWay Biotech Co., LTD.尚未招聘肝转移 | 恶性黑色素瘤
-
The First Affiliated Hospital of Zhengzhou UniversityJiangsu HengRui Medicine Co., Ltd.尚未招聘
-
Beijing Friendship Hospital未知
-
Peking Union Medical College Hospital完全的
-
Shandong UniversityThe Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second Hospital of Shandong...招聘中
-
Peking University尚未招聘
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.未知
-
The First Affiliated Hospital of Zhengzhou University招聘中
-
University of California, San FranciscoNational Cancer Institute (NCI)完全的
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing Friendship Hospital 和其他合作者尚未招聘
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.招聘中
-
The First Affiliated Hospital of Xiamen University未知Locally Advanced or Metastatic Gastric Adenocarcinoma中国
-
Hunan Cancer HospitalSuzhou Sheng Diya Biomedical Co., Ltd.主动,不招人
-
Peking Union Medical College HospitalJiangsu HengRui Medicine Co., Ltd.招聘中
-
Guangzhou Institute of Respiratory DiseaseJiangsu HengRui Medicine Co., Ltd.; BGI-Shenzhen完全的
-
Tianjin Medical University Cancer Institute and...招聘中
-
Fujian Medical University尚未招聘
-
Guangdong Association of Clinical Trials尚未招聘
-
Nanfang Hospital of Southern Medical UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.招聘中
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.招聘中BCLC 分类中的 C 期肝细胞癌中国
-
Northwestern UniversityGlaxoSmithKline; Celgene Corporation完全的
-
Fujian Cancer Hospital尚未招聘
-
Fudan University未知
-
GlaxoSmithKline完全的肿瘤,乳腺美国, 澳大利亚, 加拿大, 德国, 阿根廷, 波兰, 俄罗斯联邦, 比利时, 西班牙, 拉脱维亚, 荷兰, 新西兰, 墨西哥, 巴基斯坦, 意大利, 奥地利, 智利, 秘鲁, 南非, 捷克共和国, 匈牙利, 大韩民国, 斯洛伐克, 巴西, 火鸡
-
The First Affiliated Hospital of Xiamen University招聘中
-
The Affiliated Hospital of Qingdao University未知
-
Hunan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.招聘中
-
Jiangsu HengRui Medicine Co., Ltd.主动,不招人根治性切除或消融后复发风险高的肝细胞癌 (HCC) 患者的辅助治疗中国